New partnership will increase access to BioSkryb’s industry-leading single-cell multiomics technology
DURHAM, N.C. – September 26, 2024 - BioSkryb Genomics,a company ushering in the next generation of single-cell technology, today announced a partnership with the Human Cell Atlas (HCA), a global con…
In today's post, we have the pleasure of presenting an exclusive interview with our very own Stephanie Scherer PhD, Manager of Scientific Engagement at BioSkryb Genomics. She is our in-house CRISPR expert and enthusiast, and she will share her insights on why CRISPR is such an important scientific a…
BioSkryb will highlight its new automation-ready ResolveDNA® and ResolveOME™ single-cell core kits, and share new breast cancer research and a spotlight presentation
DURHAM, N.C. – March 28, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight…
New ResolveDNA® and ResolveOME™ single-cell kits generate sequencing-ready libraries in under eight hours
DURHAM, N.C. – March 13, 2024 - BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome a…
BioSkryb to introduce new products and novel applications of industry-leading portfolio that advance the single-cell multiomics field through simultaneous interrogation of DNA, RNA, and targeted proteins from each cell
DURHAM, N.C. – January 30, 2024 - BioSkryb Genomics, a company transforming singl…
Ram Laxman brings executive leadership experience from 10x Genomics, Illumina, and Pacific Biosciences to expand BioSkryb’s international footprint
DURHAM, N.C. – November 29, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of th…
BioSkryb will participate in two CoLab Sessions on single-cell whole genome sequencing and four poster presentations with new pancreatic and breast cancer data
DURHAM, N.C. – October 30, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic vie…
As a part of the National Institute of Standards and Technology (NIST) Genome Editing Consortium, BioSkryb will help enable increased confidence in gene edited research and commercial products
DURHAM, N.C. – September 13, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by e…
Strategic distribution agreement with Research Instruments expands access to BioSkryb’s best-in-class single-cell multiomics portfolio throughout Southeast Asia
DURHAM, N.C. – August 30, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic…
U.S. issued patent expands BioSkryb’s IP portfolio to four granted patents in key geographic markets worldwide
DURHAM, N.C. – August 17, 2023 - BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to…
